Waldeström macroglobulinaemia relapsing with focal bone disease and achieving major response with single-agent zoledronic acid.
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Aziz
A
Bakhous
Hongyun
H
Zhu
Sarah
S
Waheed
D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001862:Bone Resorption; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000008:administration & dosage; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D064847:Multimodal Imaging; D010014:Osteolysis / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000209:etiology; D049268:Positron-Emission Tomography; D011719:Pyrazines / Q000008:administration & dosage; D012008:Recurrence; D012074:Remission Induction; D000069283:Rituximab; D014057:Tomography, X-Ray Computed; D008258:Waldenstrom Macroglobulinemia / Q000150:complications / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000601:surgery; D000077211:Zoledronic Acid
D058846:Antibodies, Monoclonal, Murine-Derived; D050071:Bone Density Conservation Agents; D001897:Boronic Acids; D004164:Diphosphonates; D007093:Imidazoles; D011719:Pyrazines; D000069283:Rituximab; D000069286:Bortezomib; D000077211:Zoledronic Acid; D003907:Dexamethasone; D008558:Melphalan